s6k1

S6K1 (RPS6KB1)

The canonical translational-effector kinase downstream of mTORC1. S6K1 sits at the nexus of nutrient sensing, protein synthesis, and negative-feedback insulin resistance — and its genetic ablation is the first direct evidence that an mTORC1 substrate governs mammalian lifespan ¹.

Identity

• UniProt: P23443 (KS6B1_HUMAN)
• NCBI Gene: 6198
• HGNC symbol: RPS6KB1
• Ensembl: ENSG00000108443
• Mouse ortholog: Rps6kb1 (one-to-one; functionally conserved)
• GenAge-models ID: 72508 — classified “anti-longevity” (KO increases lifespan)
• Length: 525 amino acids (canonical isoform Alpha-1); shorter Alpha-2 isoform (502 aa) is the form used in most biochemical studies

Nomenclature note: Literature widely uses Thr389 for the principal mTORC1 phosphorylation site; this is numbering from the shorter Alpha-2 isoform. The UniProt canonical sequence (Alpha-1, P23443) numbers the equivalent residue Thr412. Both refer to the same hydrophobic-motif phosphorylation event; Thr389 is used throughout this page to match the primary literature.

Key functional domains

• TOS (TOR-signaling) motif (residues 28–32) — required for raptor-mediated docking to mTORC1; deletion abolishes Thr389 phosphorylation
• Protein kinase domain (residues 91–352) — catalytic AGC-family kinase domain
• AGC-kinase C-terminal domain (residues 353–423) — contains the hydrophobic-motif (HM) site Thr389 phosphorylated by mTORC1; phosphorylation opens the active conformation
• Autoinhibitory domain (residues 424–525) — blocks substrate access in unstimulated conditions; requires multi-site phosphorylation to relieve inhibition

Activation mechanism

S6K1 activation requires sequential multi-site phosphorylation:

1. mTORC1 phosphorylates Thr389 (hydrophobic motif) — the rapamycin-sensitive “gate-opening” event; serves as the standard pharmacodynamic readout of mTORC1 activity in vitro and in clinical trials
2. PDK1 phosphorylates Thr229 (activation loop) — stabilises the fully active kinase conformation; requires Thr389 to be pre-phosphorylated for efficient PDK1 docking
3. Additional phosphorylations in the autoinhibitory domain (Ser441, Ser447, Ser452) relieve autoinhibition

In nutrient-replete, growth-factor-stimulated cells, mTORC1 is recruited to the lysosomal surface via the Ragulator complex, where it phosphorylates S6K1 tethered via raptor. ampk activation (low energy) suppresses mTORC1 and thereby dephosphorylates S6K1-Thr389 through PP2A phosphatases.

Downstream substrates: translational output

Activated S6K1 drives protein synthesis through at least two key substrates ²:

• rpS6 (40S ribosomal protein S6) — phosphorylated at Ser235/Ser236/Ser240/Ser244 (site numbering from rpS6 primary literature, not from Holz 2005 which identifies rpS6 only as a downstream S6K1 substrate without specifying sites); a classical marker of mTORC1 pathway activity in tissue sections; promotes translation of mRNAs with a 5’ terminal oligopyrimidine (TOP) tract unsourced (rpS6 phospho-sites require separate citation)
• eIF4B — phosphorylated at Ser422; stimulates the eIF4A RNA helicase component of the eIF4F cap-binding complex → enhanced unwinding of structured 5’UTRs → preferential translation of mRNAs encoding ribosomes, growth factors, and cell-cycle regulators

Together these substrates explain why mTORC1/S6K1 signalling biases translation towards anabolic growth programmes.

Negative feedback loop: S6K1 → IRS-1 → insulin resistance

A defining aging-relevant feature of S6K1 is its role in a negative-feedback loop that suppresses insulin signalling ³:

1. Activated S6K1 phosphorylates IRS-1 at multiple inhibitory serine/threonine sites. Mouse: Ser307, Ser632/Ser635 (per Um 2004 corrigendum, Nature 431:485 — original figure labels said S636/S639 but corrected to S632/S635 for mouse numbering). Human: Ser312, Ser636/Ser639 unchanged. Ser302 also phosphorylated by S6K1 per Harrington et al. 2004. contradictory-evidence (Ser1101 sometimes cited in other reviews but absent from Um 2006)
2. IRS-1 phosphoserine marks recruit SOCS proteins and 14-3-3 adapters → IRS-1 ubiquitylation and proteasomal degradation
3. Loss of IRS-1 reduces PI3K/AKT signalling → attenuated insulin and IGF-1 receptor signalling

This mechanism explains the paradox of mTORC1 hyperactivation causing insulin resistance: chronic overnutrition or growth-factor hyperstimulation → sustained S6K1 activity → IRS-1 degradation → apparent insulin resistance ³⁴. The feedback renders hyperactive mTOR/S6K1 nodes (as seen in obesity and aging) counterproductive for insulin action.

Dimension	Status	Notes
Pathway conserved in humans?	yes	IRS-1 serine phosphorylation and insulin resistance connection documented in human adipocytes and skeletal muscle
Phenotype conserved in humans?	yes	Type 2 diabetes-related insulin resistance involves this axis; mTOR inhibitors improve insulin sensitivity in some clinical settings
Replicated in humans?	in-progress	Mechanistic detail debated (see Rajan et al. 2013 — specific S6K1 site in human adipocytes disputed); contradictory-evidence

Role in aging

S6K1 knockout mice are long-lived

The first and most compelling genetic demonstration that an mTORC1 substrate influences mammalian lifespan is the S6K1-knockout mouse ¹:

• Female S6K1-null mice showed a statistically significant lifespan extension (log-rank χ²=11.07, p<0.001; n=29 KO vs n=23 WT females); the exact median extension percentage is unverifiable from abstract alone — the wiki previously stated ~9% but the GenAge-models entry (ID 72508) records 19% lifespan change (unclear whether median or maximum) no-fulltext-access (Selman 2009 is closed-access; full-text quantitative figures not confirmable)
• Male S6K1-null mice showed no significant lifespan extension — a sex-specific effect that remains mechanistically unexplained no-mechanism
• KO mice were resistant to age-related pathologies including lordokyphosis, reduced immune function, and motor dysfunction
• Despite increased food intake (elevated hunger), KO mice remained lean — pointing to altered adipose metabolism
• Metabolic profiling showed gene expression patterns resembling caloric restriction (CR): upregulated fatty acid oxidation, reduced expression of lipogenic genes
• S6K1 KO recapitulates several CR hallmarks without reducing caloric intake — phenocopying an mTORC1 inhibitory state needs-replication (single study; independent genetic models desirable)

Dimension	Status	Notes
Pathway conserved in humans?	yes	mTORC1/S6K1 circuit structurally conserved
Phenotype conserved in humans?	unknown	No equivalent genetic model exists; indirect evidence from rapamycin studies
Replicated in humans?	no	needs-human-replication

Age-related S6K1 hyperactivation

In aged tissues, basal mTORC1/S6K1 activity is elevated relative to young tissues in multiple model systems, contributing to:

• Anabolic resistance in skeletal muscle: elevated basal S6K1 activity may paradoxically impair post-prandial translational bursts via sustained IRS-1 inhibition, contributing to sarcopenia contradictory-evidence (see Horwath 2025 — lean older men may maintain anabolic sensitivity via compensatory mechanisms)
• Senescent-cell anabolic phenotype: senescent cells exhibit mTORC1/S6K1 hyperactivation, driving the production of SASP factors and autophagy suppression; rapamycin attenuates the SASP partly via S6K1 inhibition no-mechanism (the exact contribution of S6K1 vs other mTORC1 substrates to SASP is not fully resolved)
• Impaired autophagy: S6K1-mediated phosphorylation of the autophagy initiator ULK1 (at Ser757) reduces autophagy flux, converging on the disabled-macroautophagy hallmark

Rapamycin as a pharmacological S6K1 readout

pThr389-S6K1 is the standard pharmacodynamic endpoint for mTORC1 inhibitors in both preclinical and clinical settings. Rapamycin acutely and potently dephosphorylates S6K1-Thr389 with higher sensitivity than 4ebp1 dephosphorylation — a pharmacological asymmetry with mechanistic implications: chronic rapamycin may spare 4EBP1 phosphorylation while maintaining S6K1 inhibition, depending on dose and tissue. This asymmetry matters because the 4ebp1–eIF4E axis (not S6K1) may dominate oncogenic translational control contradictory-evidence.

Druggability — tier-2 (re-rated 2026-05-08). No S6K1-selective pharmacological agent is FDA-approved or in late-stage clinical development; rapamycin and rapalogs (everolimus, temsirolimus — FDA-approved for transplant + oncology) act on the upstream mTORC1 complex and dephosphorylate S6K1 indirectly. The earlier tier-1 designation reflected (a) the S6K1-knockout mouse lifespan extension (Selman 2009 — first direct genetic evidence that an mTORC1 substrate governs mammalian lifespan), (b) S6K1’s position as the canonical pharmacodynamic readout for the lifespan-extending mTORC1 axis, and (c) upstream rapamycin/rapalog clinical access to the pathway — but the strict Open Targets criterion (Approved Drug = true for S6K1 itself in an aging indication) does not apply, and upstream-only pharmacology does not justify tier-1 for S6K1 the protein. Tier-2 (“high-quality probe”) accurately reflects the current state. Aging-axis centrality via the rapamycin/mTORC1 program is unchanged and is documented on rapamycin and mtor.

Pathway membership

• mtor — direct mTORC1 substrate; reciprocally inhibits mTORC2 via phosphorylation of Rictor (Thr1135) unsourced for the Rictor site detail — confirm with primary source
• insulin-igf1 — negative feedback via IRS-1 phosphoserine; integrates nutrient and hormonal signals
• translation-regulation — anabolic effector via rpS6 and eIF4B phosphorylation
• ampk — AMPK→TSC1/2→RHEB cascade suppresses mTORC1→S6K1; AMPK also phosphorylates Raptor directly

Key interactors

• raptor — mTORC1 scaffold; TOS-motif docking partner; obligatory for Thr389 phosphorylation
• 4ebp1 — parallel mTORC1 substrate; competes for translational output control; their relative phosphorylation distinguishes acute vs chronic rapamycin effects
• irs-1 — negative-feedback phosphorylation substrate; links S6K1 to insulin resistance
• pdpk1 — activating kinase (Thr229); acts downstream of PI3K/AKT
• rps6 — downstream substrate; classical readout of S6K1 activity in tissue IHC
• eif4b — downstream substrate; links S6K1 to 5’cap-dependent translation initiation

Limitations and gaps

• Sex-specific longevity effect in S6K1 KO mice is unexplained: females live longer, males do not ¹. This limits extrapolation and suggests either sex-hormone interactions or sex-biased metabolic compensation. no-mechanism
• Specific IRS-1 sites phosphorylated by S6K1 in intact human cells remain disputed: Rajan et al. 2013 (doi:10.1371/journal.pone.0059725) found S6K1 does not phosphorylate IRS-1 Ser307 in human primary adipocytes despite rapamycin sensitivity — an unidentified kinase may act downstream of mTOR. contradictory-evidence
• No human genetic longevity association for RPS6KB1 variants confirmed in GWAS. Genetic evidence confined to mouse KO. needs-human-replication
• S6K1 vs S6K2 redundancy: a closely related paralog (S6K2, RPS6KB2) has overlapping substrates; which functions are S6K1-specific vs shared is incompletely resolved. no-mechanism
• Tissue-specific roles: S6K1 has distinct roles in liver (lipid metabolism), adipose (lipolysis), brain (synaptic plasticity), and muscle (protein synthesis). Aging effects may differ substantially by tissue. needs-replication

Footnotes

Footnotes

1. selman-2009-s6k1-lifespan · n=52 females (29 KO, 23 WT); male cohort size not confirmed from abstract · in-vivo (mouse, S6K1-null genetic KO) · p<0.001 log-rank · model: S6K1-/- vs WT Mus musculus (C57BL/6 background) · doi:10.1126/science.1177221 · no-fulltext-access (closed-access; exact lifespan % not verifiable) ↩ ↩² ↩³

2. holz-2005-mtor-s6k1-translation · in-vitro (cell lines, mechanistic biochemistry) · model: HEK293E cells (also U2OS and HeLa) · doi:10.1016/j.cell.2005.10.024 ↩

3. um-2006-s6k1-insulin-resistance · review · model: mouse S6K1 KO (Um et al. 2004) and cell-line/human infusion studies reviewed · doi:10.1016/j.cmet.2006.05.003 ↩ ↩²

4. copps-2012-irs-phosphorylation · systematic-review · n=multiple cohorts reviewed · model: in-vivo and in-vitro human and mouse · doi:10.1007/s00125-012-2644-8 ↩